Skip to main content

Drug-Induced Hepatotoxicity!

 DRUG-INDUCED HEPATOTOXICITY

"Hepatotoxicity is the injury or liver damage caused by exposure to certain drugs, when taken in overdoses and sometimes when administered at therapeutic ranges, may injure the organ".

  • Drug-induced hepatotoxicity is also referred to as the Drug-Induced Liver Injury (DILI).

Physiological functions of liver:

  1. Formation and sensation of bile.
  2. Nutrient and vitamin metabolism (amino acid, lipid).
  3. Detoxification and inactivation of various substances (toxin drugs).
  4. Synthesis of plasma proteins (Albumin, clotting factors).
  5. Immune systems (Kupffer cells).

  • Hepatotoxicity is most prevalent in older patients especially in those with pre-existing hepatic impairment.


The few examples of drugs that cause hepatotoxicity are listed below:

1. ACE Inhibitors:

  • Hepatic injury occurs occasionally with ACE-Inhibitors.
  • Captopril and Enalapril are implicated in most reported cases, but others also have similar hepatotoxic potential.
  • Most cases show cholestatic injury, but mixed and hepatocellular damage are also reported.

2. Acetaminophen:

  • Acetaminophen is a widely used drug found in many over the counter and prescription analgesics medicine.
  • In adults, toxicity may occur by ingestion of >7.5-10 g over a period of 8hrs. or less.
  • Acetaminophen is metabolized in the liver by conjugation to non-toxic glutathione. The conjugated product is eliminated in urine. But in acute overdoses, the livers normal glutathione reserves are depleted, and the excess acetaminophen is then metabolized to highly toxic metabolite N-Acetyl-p-benzoquinone (NABQI), causing hepatocellular death and liver cell necrosis.
  • Alcohol consumption increase Acetaminophen toxicity.
  • Hepatitis is reported in patients taking large Acetaminophen doses for therapeutic purposes.


3. Alcohol:

  • Ethanol is oxidized in liver to Acetaldehyde that results in injury to cells and mitochondria with striking impairment of O2 utilization.
  • Fatty infiltration of liver occurs in 70-100% of alcoholic.
  • 30% alcoholics develop alcoholic hepatitis and 10% develop liver cirrhosis.
  • Alcohol can also enhance the hepatotoxicity of other drugs.
  • Malnutrition can potentiate alcoholic disease.


4. Antidepressants, Heterocyclics:

  • The prevalence of hepatic injury is estimated to be 1%; with most cases presenting as cholestasis.
  • The idiosyncratic reaction resembles the cholestasis associated with Phenothiazine.


5. Cephalosporins:

  • Transient-minor increase in AST, ALT, and Alkaline phosphate occur frequently.
  • Ceftriaxone use is associated with development of "gallbladder sludge" in up to 25% of patients.


6. Contraceptives, Oral:

  • Data from two large, long-term cohort studies did not detect any association between oral contraceptives use and serious liver disease.
  • One study detected an increase in the frequency of mild-liver diseases among users of older, high estrogen products.
  • Frequency of gall-bladder disease was also increased by older oral contraceptives.


7. Gold-Salts:

  • Cholestasis occur occasionally with normal doses of parenteral gold salts.
  • Hypersensitivity is the suspected mechanism.
  • Onset is commonly with first few weeks of therapy and recovery usually occur 3 months after drug discontinuation.
  • Lipo-granulomas are frequently found in liver biopsy of parenteral gold-treated patients.
  • Hepatic necrosis can result from overdose.


8. Histamine H2-Receptor Antagonists:

  • Cimetidine and Ranitidine are associated with increased liver enzymes.
  • Risk of acute liver injury (ALI) with cimetidine is about 1/5000 with most cases occurring during first 2 months of use.


9. NSAIDs:

  • The incidence of clinically apparent hepatic injury from non-salicylates NSAIDs estimated to be 1/10000 patients.
  • The incidence for Sulindac may be 5-10 times higher than for other non-salicylate NSAIDs. 50% reaction to Sulindac are cholestatic 25% hepatocellular.

10. Penicillin:

  • Cloxacillin and Flucloxacillin are associated with cholestatic hepatitis.
  • The effect is reversible but can persist for months after drug discontinuation.


11. Steroids, C-17-a-Alkyl:

  • Canalicular cholestasis occurs with a minimal amount of hepatic inflammation.
  • Prevalence appears to be dose related.
  • Jaundice may or may not be preceded by clinical signs and usually follows 1-6 months therapy.
  • Examples are: Methyltestosterone, Oxymetholone, Oxandrolone.


12. Vitamin A:

  • Hepatomegaly, portal hypertension and mild increase in liver enzyme leads are common features of Vitamin A.
  • Central vein sclerosis and perisinusoidal fibrosis which can progress to cirrhosis have also been reported in Vit-A toxicity. These affects are associated with doses >50000 IU/day.
  • Hepatotoxicity is possible with acute doses >600000IU/day.

Labels:

Comments

Post a Comment

Popular posts from this blog

Diabetes Mellitus: Types!

TYPES OF DIABETES MELLITUS 1. TYPE1 DM Type 1 DM is usually diagnosed before age 30 years, but it can develop at any age. T1DM is an autoimmune disease in which insulin producing B-cells are destroyed. The presence of Human Leucocyte Antigens (HLAs ) is associated with the development of T1DM. In addition, these individuals often develop Islet cell antibodies , Insulin Autoantibodies or Glutamic Acid decarboxylase autoantibodies . At the time of development of diagnosis of T1DM, it is usually believed that most of the patients have 80-90%loss of beta cells. The remaining beta cells function at the diagnosis creates a " HONEYMOON PERIOD" during which the blood glucose levels are easier to control, and smaller amounts of insulin are required. after this, the remaining beta cells function is completely lost, and the patients become completely deficient of insulin and hence require exogenous insulin.  2. TYPE1.5 DM:  Also referred as Latent autoimmune diabetes in Adults (LAD)
Post a Comment
Read more

Diabetes Mellitus: Pharmacotherapy- Gliptins and a-Glycoside Inhibitors!

  PHARMACOTHERAPY:  Medications classifications include:  Sulfonyl Urea's Nonsylfonylurea Secretagogues (a-Glinides) Biguanides Thiazolidinediones a-Glucosidase Inhibitors Dipeptidyl Peptidase-4 Inhibitors (Gliptins) Sodium-glucose co-transporter (SGLT) Inhibitors  Central-Acting Dopamine Agonists Bile Acid Sequestrants Insulin therapy 5. a-GLUCOSIDASE INHIBITORS Acarbose and Miglitol are a-glucosidase inhibitors currently approved in the United States. Mechanism of Action: An enzyme that is along the brush border of the intestine cells called a-glucosidase; breaks down the complex carbohydrates into simple sugars, resulting in absorption. The a-glucosidase inhibitors work by delaying the absorption of carbohydrates from the intestinal tract, which reduces the rise in postprandial glucose levels. Therapy: As a monotherapy , a-glucosidase inhibitors primarily reduce post-prandial glucose excursions.  Clinical Use: FPG concentrations have been decreased by 40-50mg/dL and A1c level
Post a Comment
Read more

GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)!

MANAGEMENT OF GASTRO-ESOPHAGEAL REFLUX DISEASE  "GERD refers to the endoscopically determined esophagitis or endoscopy-negative reflux disease" . "GERD is the term used to describe any symptomatic clinical condition or histopathological alteration resulting from episodes of reflux of acid, pepsin and occasionally, bile into the esophagus from the stomach". Patients with uninvestigated "reflux-like" symptoms should be managed as patients with uninvestigated dyspepsia. There is currently no evidence that H.pylori should be investigated in patients with GERD. Symptoms: Heartburn is the characteristic symptom of GERD. Acid regurgitation Dysphagia Belching Upper abdominal discomfort Bloating and postprandial fullness Chest pain Hoarseness Cough Complications include: Esophageal ulceration Formation of specialized columnar-lined esophagus at the gastro-esophageal junction known as Barretts Esophagus . Mechanism of Acid Reflux: The mechanism of acid reflux is mu
Post a Comment
Read more